Encrypted login | home

Program Information

Dosimetric Investigation of Praseodymium-142 Microspheres for Microsphere Brachytherapy of Nonresectable Hepatic Tumor


M Ferreira

M Ferreira*, T Podder, J Jung, East Carolina University, Greenville, NC

WE-A-BRB-8 Wednesday 8:00:00 AM - 9:55:00 AM Room: Ballroom B

Purpose: To evaluate the dosimetric parameters of Praseodymium-142 (¹⁴²Pr) glass microspheres and its potential application in microsphere brachytherapy of nonresectable hepatic tumor for faster dose delivery and facilitated quality assurance, while maintaining comparable dose distribution of the currently used radionuclides. Methods: Dose profiles for a ¹⁴²Pr point source were obtained using BRAIN-DOSE dose point kernel code and MCNPX2.6 Monte Carlo simulation. Microspheres containing ¹⁴²Pr were studied and their dose distributions were compared to the doses of the currently used radionuclide Yittrium-90 (⁹⁰Y). Dose distributions due to glass microspheres ensembles within different sizes of spherical tumors were simulated. Physical properties, e.g. time to deliver 90% of the total dose for ¹⁴²Pr and ⁹⁰Y, were studied. Results: Dose rates from BRAIN-DOSE calculation for ¹⁴²Pr and ⁹⁰Y were 4.42 mGy/hr and 5.53 mGy/hr at 0.5 cm away from a 1 µCi source. From MCNPX2.6 the beta dose per decay at the tumor center for ¹⁴²Pr and ⁹⁰Y were 2.02 x 10⁻¹² Gy and 2.36 x 10⁻¹² Gy, respectively, for a tumor of 2.5 cm radius. For this case, simulation showed that the total dose in the tumor vicinity and therefore to adjacent organs due to the gamma yield was small, e.g. 0.03 Gy at 10 cm from the tumor center for 150 Gy total physical dose. Conclusions: Total dose per decay due to beta emissions were similar for both ¹⁴²Pr and ⁹⁰Y. Shorter half-life is an advantage of ¹⁴²Pr, enabling faster dose delivery. The physical properties of ¹⁴²Pr make it suitable for microsphere brachytherapy. Total gamma contribution of ¹⁴²Pr was small, therefore may not be clinically relevant. Gamma radiation, however, opens possibilities for quality assurance, biodistribution imaging and dose distribution assessments.

Contact Email